Observes a donor stem cell transplant in people with multiple myeloma
Follows people with multiple myeloma who receive a donor stem cell transplant.
Plain-language title generated from the registry record
Registry title: Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Key facts
- Where
- Minneapolis, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people on Medicare who have stage II or III multiple myeloma and/or primary plasma cell leukemia and will get a stem-cell transplant from a donor.
- Sex
- All sexes can join.
- Disease stage
- Stage II or III multiple myeloma and/or primary plasma cell leukemia.
Read by machine on 9 November 2026.
Where in United States
- Center for International Blood and Marrow Transplant ResearchMinneapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Center for International Blood and Marrow Transplant Research
- Trial code
- NCT03127761
- Record updated
- 30 August 2023
- Original description
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients.Read full original descriptionShow less
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients.
Thus, although potentially curative, standard risk MM patients have excellent prognoses in the era of novel therapies which reduces the overall benefit of alloHCT. However, because the outcomes for high-risk MM remain poor despite the best available standard therapies (overall survival of 24-36 months), initial data suggest that alloHCT should be explored in this subset.
Inclusion: Medicare beneficiary; Stage II or III multiple myeloma and/or primary plasma cell leukemia; Eligible to receive an allogeneic HCT from any suitable allogeneic donor (as determined by the transplant center) including umbilical cord blood; Will receive allogeneic HCT at a US transplant center; Agree to submit comprehensive clinical data on their pre- and post-transplant clinical status and outcomes to the CIBMTR.